Cargando…
Immunotherapy for Dogs: Running Behind Humans
A number of excellent reviews on the potential of canine cancer immunotherapy are available, but many extrapolate from observations in humans when in fact only very few immunotherapies have been developed for canines that have shown efficacy in well-designed studies. Pharmaceutical and biotech compa...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807660/ https://www.ncbi.nlm.nih.gov/pubmed/29459862 http://dx.doi.org/10.3389/fimmu.2018.00133 |
_version_ | 1783299316682588160 |
---|---|
author | Klingemann, Hans |
author_facet | Klingemann, Hans |
author_sort | Klingemann, Hans |
collection | PubMed |
description | A number of excellent reviews on the potential of canine cancer immunotherapy are available, but many extrapolate from observations in humans when in fact only very few immunotherapies have been developed for canines that have shown efficacy in well-designed studies. Pharmaceutical and biotech companies are aware that the market for more expensive immunotherapies in canines is limited resulting in limited funding for clinical trials. However, dogs and other pets deserve access to this new form of cancer therapy. The purpose of this brief review is to summarize the current status of available immunotherapies for dogs and their near-term prospects, provided we can effectively translate discoveries and progress in humans to canines. |
format | Online Article Text |
id | pubmed-5807660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58076602018-02-19 Immunotherapy for Dogs: Running Behind Humans Klingemann, Hans Front Immunol Immunology A number of excellent reviews on the potential of canine cancer immunotherapy are available, but many extrapolate from observations in humans when in fact only very few immunotherapies have been developed for canines that have shown efficacy in well-designed studies. Pharmaceutical and biotech companies are aware that the market for more expensive immunotherapies in canines is limited resulting in limited funding for clinical trials. However, dogs and other pets deserve access to this new form of cancer therapy. The purpose of this brief review is to summarize the current status of available immunotherapies for dogs and their near-term prospects, provided we can effectively translate discoveries and progress in humans to canines. Frontiers Media S.A. 2018-02-05 /pmc/articles/PMC5807660/ /pubmed/29459862 http://dx.doi.org/10.3389/fimmu.2018.00133 Text en Copyright © 2018 Klingemann. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Klingemann, Hans Immunotherapy for Dogs: Running Behind Humans |
title | Immunotherapy for Dogs: Running Behind Humans |
title_full | Immunotherapy for Dogs: Running Behind Humans |
title_fullStr | Immunotherapy for Dogs: Running Behind Humans |
title_full_unstemmed | Immunotherapy for Dogs: Running Behind Humans |
title_short | Immunotherapy for Dogs: Running Behind Humans |
title_sort | immunotherapy for dogs: running behind humans |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807660/ https://www.ncbi.nlm.nih.gov/pubmed/29459862 http://dx.doi.org/10.3389/fimmu.2018.00133 |
work_keys_str_mv | AT klingemannhans immunotherapyfordogsrunningbehindhumans |